JP2022538642A5 - - Google Patents

Info

Publication number
JP2022538642A5
JP2022538642A5 JP2021577641A JP2021577641A JP2022538642A5 JP 2022538642 A5 JP2022538642 A5 JP 2022538642A5 JP 2021577641 A JP2021577641 A JP 2021577641A JP 2021577641 A JP2021577641 A JP 2021577641A JP 2022538642 A5 JP2022538642 A5 JP 2022538642A5
Authority
JP
Japan
Prior art keywords
compound
treatment
lmtx
therapeutic composition
neurotransmitter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577641A
Other languages
English (en)
Japanese (ja)
Other versions
JP7638915B2 (ja
JP2022538642A (ja
Filing date
Publication date
Priority claimed from GBGB1909493.7A external-priority patent/GB201909493D0/en
Application filed filed Critical
Publication of JP2022538642A publication Critical patent/JP2022538642A/ja
Publication of JP2022538642A5 publication Critical patent/JP2022538642A5/ja
Application granted granted Critical
Publication of JP7638915B2 publication Critical patent/JP7638915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577641A 2019-07-01 2020-06-30 ロイコメチルチオニニウムの治療上の相互作用 Active JP7638915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909493.7 2019-07-01
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Publications (3)

Publication Number Publication Date
JP2022538642A JP2022538642A (ja) 2022-09-05
JP2022538642A5 true JP2022538642A5 (enExample) 2023-07-10
JP7638915B2 JP7638915B2 (ja) 2025-03-04

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577641A Active JP7638915B2 (ja) 2019-07-01 2020-06-30 ロイコメチルチオニニウムの治療上の相互作用

Country Status (12)

Country Link
US (1) US20230031369A1 (enExample)
EP (1) EP3989954A1 (enExample)
JP (1) JP7638915B2 (enExample)
KR (1) KR20220027203A (enExample)
CN (1) CN114126622A (enExample)
AU (1) AU2020298758B2 (enExample)
BR (1) BR112021025256A2 (enExample)
CA (1) CA3143790A1 (enExample)
GB (1) GB201909493D0 (enExample)
IL (1) IL289338B2 (enExample)
MX (1) MX2021015292A (enExample)
WO (1) WO2021001380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
GB202500018D0 (en) * 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações

Similar Documents

Publication Publication Date Title
JP2020519661A5 (enExample)
CN1104892C (zh) 采用神经保护剂治疗耳鸣的方法
JP2024516371A5 (enExample)
JP2022191257A5 (enExample)
JP2007509055A (ja) [2−(8,9−ジオキソ−2,6−ジアザビシクロ[5.2.0]ノナ−1(7)−エン−2−イル)アルキル]ホスホン酸および誘導体の経口投与
JP2022537047A5 (enExample)
JP2022539185A5 (enExample)
JP2016534063A5 (enExample)
JP2012111764A5 (enExample)
JP2019516684A5 (enExample)
TW201622721A (zh) S1p調節劑之立即釋放劑量療法
JP2022553954A5 (enExample)
JP2011505356A5 (enExample)
JP2016537432A5 (enExample)
JP2019526571A5 (enExample)
JP2022554276A5 (enExample)
JP2012510985A5 (enExample)
JP2024503727A5 (enExample)
JP2022552520A5 (enExample)
JP2021534160A5 (enExample)
JP2025118775A5 (enExample)
JP2007530703A5 (enExample)
JP2023502053A5 (enExample)
EP4108240A3 (en) Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3
JP2019531286A5 (enExample)